Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
Financials
Financial year 2025
GEN PHARM from Brussel, company number BE0897952853, closed financial year 2025 with a result of € -5,339 after tax. For that financial year GEN PHARM recorded a gross margin of € -5,653 and equity of € 9,381. Compared with financial year 2024, the result moved from € -4,116 to € -5,339. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.
€ 9,381
▼ 36% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -5,339
▼ 30 % more loss than in 2024
Profit after tax over the fiscal year.
Loss, nothing to pay out
Reserves fell to € -52,119.
People and assets in 2025
0
Average over the fiscal year, from the social balance sheet.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 775
▲ € 747 vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -3,866 | € -4,106 | € -4,460 | € -5,653 | ▼ € 1,192 |
| Profit after taxes | € -2,582 | € -3,238 | € -4,116 | € -5,339 | ▼ € 1,223 |
| Equity | € 22,074 | € 18,836 | € 14,720 | € 9,381 | ▼ 36% |
| Total debts | € 1,862 | € 1,543 | € 1,527 | € 2,275 | ▲ 49% |
| Retained profit | € -39,426 | € -42,664 | € -46,780 | € -52,119 | ▼ € 5,339 |
| Balance sheet total | € 23,936 | € 20,379 | € 16,247 | € 11,656 | ▼ 28% |
Key figures of GEN PHARM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to GEN PHARM?
What happened at GEN PHARM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Eric-Jan Ostwald stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 5,339. Source: NBB ↗
- Eric-Jan Ostwald became a director. NBB
- New establishment in Brussel. KBO
- Start of the company according to the CBE. KBO
In short
From € 2,582 loss in 2022 to € 5,339 loss in 2025.
A new publication or filing at GEN PHARM? We notify you, reason included.
Follow GEN PHARMDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by Ostwald Beheer (96%) and Eric-Jan Ostwald (4%).
Directors
According to the 2025 annual accounts
Eric-Jan Ostwald
Director
Owns 4% directly
since 2025 · until 2031
Shareholders
Ostwald Beheer
96%
Eric-Jan Ostwald · director
4%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Kantersteen 47
1000 Brussel
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0897.952.853
- VAT number
- BE 0897.952.853
- Registered office
- Kantersteen 47, 1000 Brussel
- Names & denominations
- GEN PHARM
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 16 May 2008
- Peppol
- Active · Active since 21 Nov 2025
- Activities · NACE
Overige rechtskundige dienstverlening
Overige zakelijke dienstverlening, neg